levodopa-carbidopa
Sponsors
Shahid Beheshti University of Medical Sciences, Osmotica Pharmaceutical US LLC, AbbVie, Beirut Eye Specialist Hospital, Centre Hospitalier Universitaire Vaudois
Conditions
Drug EffectNonarteritic Anterior Ischemic Optic NeuropathyParkinson DiseaseParkinson's DiseaseRetinitis PigmentosaSpinal Cord Injuries
Phase 1
A Pharmacokinetic Study of Levodopa and Carbidopa Intestinal Gel in Subjects With Advanced Parkinson's Disease
CompletedNCT01484990
Start: 2010-04-30End: 2010-09-30Updated: 2017-11-21
Acute Effects of Pharmacological Neuromodulation on Leg Motor Activity in Patients With SCI Treated With EES
CompletedNCT04052776
Start: 2020-09-11End: 2023-10-04Updated: 2023-10-05
Phase 2
Efficacy, Safety, and Pharmacokinetics/Pharmacodynamic Study of L-Dopa/Carbidopa To Treat Parkinson's Disease
CompletedNCT00558337
Start: 2007-11-30End: 2008-12-31Updated: 2009-01-14
Studying a Potential Protective Effect of L-Dopa on Retinitis Pigmentosa
NCT02837640
Start: 2016-06-30End: 2021-06-30Target: 50Updated: 2016-07-19
Clinical Study to Evaluate the Possible Efficacy of Metformin in Patients With Parkinson's Disease
CompletedNCT05781711
Start: 2023-01-06End: 2025-01-20Updated: 2026-03-13
Montelukast in Parkinson Disease
RecruitingNCT06113640
Start: 2023-11-05End: 2026-12-20Target: 60Updated: 2026-03-13
Role of Silymarin in Neuroprotection and Symptom Management in Parkinson's Disease
RecruitingNCT07001150
Start: 2025-05-10End: 2026-05-30Target: 50Updated: 2025-09-10